Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's Bloomage Forms Botox JV with Medytox of South Korea

publication date: Jul 29, 2015
Bloomage BioTechnology formed a JV with South Korea's Medytox to market Medytox's version of the wrinkle treatment Botox (Botulinum Toxin) in China. The JV, which will be owned 50-50 by the two partners, will be called Medybloom. Bloomage is already involved in China's aesthetic care market as a producer of hyaluronic acid. It markets various grades of HA in China as orthopedic injections, ophthalmic solutions, cosmetic fillers, surgical anti-adhesion products and food supplements. More details....

Stock Symbols: (HK: 00963) (KS: 086900)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital